| アブストラクト | BACKGROUND: Besides hemorrhage, allergic reactions have also been observed in several clinical trials of fibrinolytic agents. These reactions might negatively affect patient outcomes, especially life-threatening type I hypersensitivity reactions such as anaphylaxis. However, there are limited data on the incidence of these reactions. OBJECTIVE: The aim of study was to analyze the incidence of urticaria, angioedema, and type I hypersensitivity reactions from fibrinolytic agents for various indications. METHODS: A retrospective analysis of data from the Thai Vigibase database was conducted. All reports of adverse drug reactions from fibrinolytic agents from 1984 to 2017 were identified using the World Health Organization adverse reaction terminology. The proportion of each suspected adverse drug reaction and the cumulative incidence were calculated. RESULTS: A total of 284 reports were identified in the Thai Vigibase database. The overall incidence of urticaria, angioedema, and type I hypersensitivity reactions for the streptokinase group was 52.64/10,000 persons, with individual incidence rates of 9.64/10,000 persons for urticaria, 8.90/10,000 persons for angioedema, and 34.11/10,000 persons for type I hypersensitivity reactions. In the alteplase group, the overall incidence for all suspected reactions was 18.90/10,000 persons, with individual incidence rates of 3.29/10,000 persons for urticaria, 5.75/10,000 persons for angioedema, and 9.86/10,000 persons for type I hypersensitivity reactions. CONCLUSIONS: Type I hypersensitivity reactions were the most common allergic reactions from fibrinolytic agents. It is necessary to take these reactions into consideration when using fibrinolytic therapy. |
|---|
| 投稿日 | 2020/5/18 |
|---|
| 投稿者 | Prasitdumrong, Hutsaya; Duangmee, Kawin; Boonmuang, Pornwalai; Santimaleeworagun, Wichai; Oppamayun, Yaowares; Sonsupap, Cholticha; Nakkaratniyom, Thawatchai |
|---|
| ジャーナル名 | Asian Pacific journal of allergy and immunology |
|---|
| 組織名 | Cardiovascular Unit, Department of Internal Medicine, Phramongkutklao Hospital,;Bangkok, Thailand.;The College of Pharmacotherapy of Thailand, The Pharmacy Council, Nonthaburi,;Thailand.;Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom,;Health Product Vigilance Center, Technical and Planning Division, Food and Drug;Administration, Ministry of Public Health, Thailand. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32416662/ |
|---|
